ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE) | WebDisclosure

Basculer en Français

10964	Companies
240023	Keywords
168772	Articles
129131	Press releases

Headlines Articles Press releases ORPHAN SYNERGY EUROPE-PHARMA

Home
Companies
ORPHAN SYNERGY EUROPE-PHARMA

PRESS RELEASE

published on 04/15/2026 at 07:30, 4 months 26 days ago

OSE Immunotherapeutics présentera un nouvel anticorps monoclonal, first-in-class, agoniste de FPR2 dans la résolution de l’inflammation chronique au Congrès 2026 de l’AAI
OSE Immunotherapeutics annoncera un nouvel anticorps monoclonal agoniste de FPR2 pour traiter l'inflammation chronique au Congrès 2026 de l'AAI

OSE Immunotherapeutics Anticorps Monoclonal FPR2 Inflammation Chronique Congrès 2026 AAI
PRESS RELEASE

published on 04/15/2026 at 07:30, 4 months 26 days ago

OSE Immunotherapeutics to Present a Novel, First-in-Class, FPR2 Agonist Monoclonal Antibody in the Resolution of Chronic Inflammation at the AAI 2026 Meeting
OSE Immunotherapeutics to present a novel FPR2 agonist monoclonal antibody aiming to resolve chronic inflammation at the AAI 2026 Meeting in Boston

OSE Immunotherapeutics Monoclonal Antibody FPR2 Chronic Inflammation Agonist
BRIEF

published on 03/16/2026 at 07:35, 5 months 26 days ago

OSE Immunotherapeutics unveils its financial calendar for 2026

Treasury Financial Calendar General Assembly OSE Immunotherapeutics 2026 Financial Results
BRIEF

published on 03/16/2026 at 07:35, 5 months 26 days ago

OSE Immunotherapeutics dévoile son calendrier financier pour 2026

Calendrier Financier Assemblée Générale Trésorerie OSE Immunotherapeutics Résultats Financiers 2026
BRIEF

published on 03/16/2026 at 07:35, 5 months 26 days ago

OSE Immunotherapeutics dévoile son calendrier financier pour 2026

Calendrier Financier Assemblée Générale Annuelle Relations Avec Les Investisseurs Industrie Biotechnologique Immunothérapies OSE
BRIEF

published on 03/16/2026 at 07:35, 5 months 26 days ago

OSE Immunotherapeutics Unveils 2026 Financial Calendar

Annual General Meeting Investor Relations Financial Calendar Biotech Industry OSE Immunotherapeutics
PRESS RELEASE

published on 03/16/2026 at 07:30, 5 months 26 days ago

OSE Immunotherapeutics annonce son calendrier financier pour 2026
OSE Immunotherapeutics annonce son calendrier financier 2026 incluant résultats, trésorerie et AG des actionnaires. Société de biotechnologie en IO et I&I. Informations prospectives

Biotechnologie Calendrier Financier Déclarations Prospectives Immuno-oncologie OSE Immunotherapeutics
PRESS RELEASE

published on 03/16/2026 at 07:30, 5 months 26 days ago

OSE Immunotherapeutics Announces its 2026 Financial Calendar
OSE Immunotherapeutics announces its 2026 financial calendar, including key dates for financial updates and statements, and annual general meeting

Annual General Meeting Financial Updates Biotech Company OSE Immunotherapeutics 2026 Financial Calendar
BRIEF

published on 01/21/2026 at 18:05, 7 months 20 days ago

FDA Grants Orphan Drug Status to OSE Immunotherapeutics' Pegrizeprument

OSE Immunotherapeutics FDA Orphan Drug Pegrizeprument Organ Transplantation Veloxis Pharmaceuticals
BRIEF

published on 01/21/2026 at 18:05, 7 months 20 days ago

La FDA accorde le statut de médicament orphelin au pegrizéprument d'OSE Immunotherapeutics

Transplantation D'organes Pegrizeprument Veloxis Pharmaceuticals Immunothérapies OSE Médicament Orphelin De La FDA

Accesswire

Published on 09/11/2026 at 04:00, 7 hours 27 minutes ago

Torq Announces Debt Settlement and Corporate Update
Published on 09/10/2026 at 22:25, 13 hours 2 minutes ago

Pathfinder Ventures Announces Appointment of Mickey Perret as Chief Executive Officer
Published on 09/10/2026 at 17:46, 17 hours 41 minutes ago

Groete Access Road Nears Completion
Published on 09/10/2026 at 15:20, 20 hours 7 minutes ago

MicroVision to Preview Next-Generation Lidar-Based Perception Platform at IAA Transportation 2026
Published on 09/10/2026 at 15:00, 20 hours 27 minutes ago

All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)

View all ACCESSWIRE

EQS Group

Published on 09/11/2026 at 10:15, 1 hour 12 minutes ago

TCMA Receives Two National Awards, Highlighting Thailand’s Cement Industry Progress Towards Net Zero 2050
Published on 09/11/2026 at 09:20, 2 hours 7 minutes ago

Cantourage Expands Portfolio with New Cannabis Active Ingredients for Innovative Compounded Medicines
Published on 09/11/2026 at 09:05, 2 hours 22 minutes ago

ROHM's New High Anti-surge Chip Resistors in "SDR01 Series" Achieve 0.33W Rated Power in 0402 Size
Published on 09/11/2026 at 09:00, 2 hours 27 minutes ago

Homann Holzwerkstoffe publishes its 2026 half-year report
Published on 09/11/2026 at 09:00, 2 hours 27 minutes ago

Picton Property Income Limited - Removal

Les Echos

Published on 09/11/2026 at 07:00, 4 hours 27 minutes ago

Transparantiekennisgeving van Baltisse Groep
Published on 09/11/2026 at 07:00, 4 hours 27 minutes ago

Transparency notification by Baltisse Group
Published on 09/11/2026 at 07:00, 4 hours 27 minutes ago

BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 4 hours 27 minutes ago

BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 15 hours 57 minutes ago

Availability of the 2026 Interim Financial Report

View all LES ECHOS COMFI WIRE